A federal judge in Chicago last Friday denied Pfizer's efforts to obtain confidential linkurl:peer review;http://www.the-scientist.com/article/display/23061/ documents related to two of its drugs from the New England Journal of Medicine, stating that any benefits of disclosing the subpoenaed documents would be "outweighed by the burden and harm that would result" to the journal. In January, Pfizer filed a linkurl:motion;http://www.the-scientist.com/blog/display/54368/ to force the NEJM to hand over peer-reviewers' comments from 11 studies relating to the arthritis drugs Bextra and Celebrex. Pfizer is currently being sued in a class-action lawsuit in a northern California federal court by patients who took the drugs, and the company argues that the manuscripts could assist in their defense. The US District Court for the Northern District of Illinois, however, rejected the claims, stating that Pfizer had not adequately explained how the peer reviews could help. Magistrate Judge Arlander Keys also wrote that "compelling production of peer...
Interested in reading more?
Become a Member of
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!